Market Research Logo

Ovarian Cancer Global Clinical Trials Review, H1, 2018

Ovarian Cancer Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2018 provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Ovarian Cancer Therapeutics, Global, Clinical Trials by Region (%), 2018*
    • Table Ovarian Cancer Therapeutics, Global, Clinical Trials by Region, 2018*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Figure 3: Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Table Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
        • Table Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
        • Table Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
        • Table Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
        • Table Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
        • Table Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Clinical Trials by G7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials
    • Table Figure 9: Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2018*
    • Table Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
    • Table Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by E7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials
    • Table Figure 12: Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2018*
    • Table Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
    • Table Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by Phase
    • Table Figure 15: Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2018*
    • Table Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase, 2018*
    • In Progress Trials by Phase
      • Table Figure 16: Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
      • Table Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Clinical Trials by Trial Status
    • Table Figure 17: Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018*
    • Table Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by End Point Status
    • Table Figure 18: Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018*
    • Table Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
    • Table Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
    • Table Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Prominent Sponsors
    • Table Figure 21: Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Table Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Top Companies Participating in Ovarian Cancer Therapeutics Clinical Trials
      • Table Figure 22: Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
      • Table Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Prominent Drugs
    • Table Figure 23: Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
    • Table Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Latest Clinical Trials News on Ovarian Cancer
    • Apr 24, 2018: TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA
    • Apr 17, 2018: Sareum Notes that Sierra Oncology will Present Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARP Inhibitors at the AACR 2018 Annual Meeting
    • Apr 16, 2018: BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
    • Apr 16, 2018: Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer
    • Apr 16, 2018: Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
    • Apr 16, 2018: Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research
    • Apr 16, 2018: Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer
    • Apr 13, 2018: Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018
    • Apr 13, 2018: TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research
    • Apr 12, 2018: TCR2 Therapeutics to Present New Preclinical Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting
    • Apr 11, 2018: Tarveda Therapeutics to Present Preclinical Data on PEN-866 in Combination with PARP Inhibitors at the 2018 AACR Annual Meeting
    • Apr 09, 2018: Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
    • Apr 05, 2018: First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer
    • Mar 29, 2018: Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018
    • Mar 28, 2018: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
    • Mar 26, 2018: Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
    • Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting
    • Mar 16, 2018: "Recombinant ANTI-EpCAM And ANTI-CD3 Human-Mouse Chimeric Bispecific Antibody For Injection" Was Granted Drug Clinical Trial Approval
    • Mar 15, 2018: TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
    • Mar 15, 2018: Phase 1 Clinical Data With Cyclacel's CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
    • Mar 15, 2018: ArQule to Present Data on miransertib at the 2018 American Association for Cancer Research (AACR) Annual Meeting
    • Mar 15, 2018: MabVax Therapeutics to present results from preclinical work on anti-cancer drug
    • Mar 14, 2018: Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting
    • Mar 14, 2018: Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi- Resistant Cancers Accepted for AACR 2018 Annual Meeting
    • Mar 08, 2018: TyrNovo to Present at BIO-Europe Spring 2018 Conference
    • Feb 22, 2018: Europe Approves JHL Biotech's Clinical Trial Application for Bevacizumab Biosimilar to Affordably Treat Colorectal, Lung, and Ovarian Cancers
    • Feb 08, 2018: Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed
    • Feb 07, 2018: GamaMabs Pharma receives Orphan Drug Designation from the US FDA for lead compound GM102
    • Jan 31, 2018: Oncoinvent: New Radspherin data published
    • Jan 31, 2018: Oncolix Sponsors Additional Research with MD Anderson Cancer Center
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report